ARMP (Armata Pharmaceuticals) Scaled Net Operating Assets: 0.75 (As of Mar. 2026)


ARMP Armata Pharmaceuticals Inc ARMP
22 GF Score
Price $6.55
! 3 Warning Signs
View Full Analysis

What is Armata Pharmaceuticals Scaled Net Operating Assets?

Armata Pharmaceuticals ARMP -10.95% 22 Scaled Net Operating Assets is 0.75 as of Mar. 2026. GuruFocus rates ARMP with a GF Score™ of 22/100. The stock has 3 warning signs investors should review.

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Armata Pharmaceuticals's operating assets for the quarter that ended in Mar. 2026 was $65.05 Mil. Armata Pharmaceuticals's operating liabilities for the quarter that ended in Mar. 2026 was $7.71 Mil. Armata Pharmaceuticals's Total Assets for the quarter that ended in Dec. 2025 was $76.88 Mil. Therefore, Armata Pharmaceuticals's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2026 was 0.75.

Armata Pharmaceuticals Scaled Net Operating Assets Historical Data

* Premium members only.

The historical data trend for Armata Pharmaceuticals's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Armata Pharmaceuticals Scaled Net Operating Assets Chart

Armata Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Scaled Net Operating Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.34 1.00 0.78 0.70 0.70

Armata Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.80 0.80 0.83 0.68 0.75

ARMP vs SRZN, ELDN, NAGE: Scaled Net Operating Assets Comparison

For the Biotechnology subindustry, Armata Pharmaceuticals's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Armata Pharmaceuticals Scaled Net Operating Assets vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Armata Pharmaceuticals's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Armata Pharmaceuticals's Scaled Net Operating Assets falls into.


ARMP
22GF Score
Armata Pharmaceuticals Inc ARMP
Scaled Net Operating Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Armata Pharmaceuticals Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Armata Pharmaceuticals's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2025 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2025 )
=(Operating Assets (A: Dec. 2025 )-Operating Liabilities (A: Dec. 2025 ))/Total Assets (A: Dec. 2024 )
=(68.194-7.46)/86.437
=0.70

where

Operating Assets(A: Dec. 2025 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=76.882 - 8.688
=68.194

Operating Liabilities(A: Dec. 2025 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=295.478 - 283.454 - 4.564
=7.46

Armata Pharmaceuticals's Scaled Net Operating Assets (SNOA) for the quarter that ended in Mar. 2026 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Mar. 2026 )
=(Operating Assets (Q: Mar. 2026 )-Operating Liabilities (Q: Mar. 2026 ))/Total Assets (Q: Dec. 2025 )
=(65.046-7.712)/76.882
=0.75

where

Operating Assets(Q: Mar. 2026 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=69.8 - 4.754
=65.046

Operating Liabilities(Q: Mar. 2026 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=381.386 - 369.081 - 4.593
=7.712

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Scaled Net Operating Assets of 0.75 mean?
Armata Pharmaceuticals (ARMP) has a Scaled Net Operating Assets of 0.75 as of Mar. 2026. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Armata Pharmaceuticals and its competitors.
Is Armata Pharmaceuticals' Scaled Net Operating Assets too high?
Armata Pharmaceuticals' current Scaled Net Operating Assets is 0.75. Overall, Armata Pharmaceuticals has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Armata Pharmaceuticals' Scaled Net Operating Assets compare to SRZN and ELDN?
Armata Pharmaceuticals' Scaled Net Operating Assets of 0.75 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Biotechnology company?
A good Scaled Net Operating Assets depends on the Biotechnology industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Armata Pharmaceuticals and its competitors. Armata Pharmaceuticals's current Scaled Net Operating Assets is 0.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Armata Pharmaceuticals stock overvalued right now?
Armata Pharmaceuticals (ARMP) has a current Scaled Net Operating Assets of 0.75. The current Scaled Net Operating Assets is 0.75. Armata Pharmaceuticals' overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Armata Pharmaceuticals (ARMP), the current Scaled Net Operating Assets is 0.75 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Armata Pharmaceuticals Business Description

Other Exchanges TG1N:Germany
Address 5005 McConnell Avenue, Los Angeles, CA, USA, 90066
Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date. The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology.
22GF Score

Get the complete analysis for ARMP

Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.55
Price